NCCN临床实践指南_慢性髓性白血病(2019.V1)英文版
-
资源ID:121183624
资源大小:1.17MB
全文页数:82页
- 资源格式: PDF
下载积分:10金贝
快捷下载
账号登录下载
微信登录下载
微信扫一扫登录
1、金锄头文库是“C2C”交易模式,即卖家上传的文档直接由买家下载,本站只是中间服务平台,本站所有文档下载所得的收益全部归上传人(卖家)所有,作为网络服务商,若您的权利被侵害请及时联系右侧客服;
2、如你看到网页展示的文档有jinchutou.com水印,是因预览和防盗链等技术需要对部份页面进行转换压缩成图而已,我们并不对上传的文档进行任何编辑或修改,文档下载后都不会有jinchutou.com水印标识,下载后原文更清晰;
3、所有的PPT和DOC文档都被视为“模板”,允许上传人保留章节、目录结构的情况下删减部份的内容;下载前须认真查看,确认无误后再购买;
4、文档大部份都是可以预览的,金锄头文库作为内容存储提供商,无法对各卖家所售文档的真实性、完整性、准确性以及专业性等问题提供审核和保证,请慎重购买;
5、文档的总页数、文档格式和文档大小以系统显示为准(内容中显示的页数不一定正确),网站客服只以系统显示的页数、文件格式、文档大小作为仲裁依据;
6、如果您还有什么不清楚的或需要我们协助,可以点击右侧栏的客服。
|
下载须知 | 常见问题汇总
|
NCCN临床实践指南_慢性髓性白血病(2019.V1)英文版
Chronic Myeloid Leukemia Version 1 2019 August 1 2018 NCCN org NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Continue Version 1 2019 08 01 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Kristina Gregory RN MSN OCN Hema Sundar PhD Continue NCCN Guidelines Panel Disclosures Hematology Hematology oncology Medical oncology Internal medicine Pathology Bone marrow transplantation Jason Gotlib MD MS Stanford Cancer Institute Gabriela Hobbs MD Massachusetts General Hospital Cancer Center Madan Jagasia MD Vanderbilt Ingram Cancer Center Hagop M Kantarjian MD The University of Texas MD Anderson Cancer Center Lori Maness MD Fred and Pamela Buffett Cancer Center Leland Metheny MD Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Joseph O Moore MD Duke Cancer Institute Arnel Pallera MD St Jude Children s Research Hospital The University of Tennessee Health Science Center Philip Pancari MD Fox Chase Cancer Center Mrinal Patnaik MD Mayo Clinic Cancer Center Enkhtsetseg Purev MD PhD University of Colorado Cancer Center Jerald P Radich MD Chair Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Michael Deininger MD PhD Vice Chair Huntsman Cancer Institute at the University of Utah Camille N Abboud MD Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine Jessica K Altman MD Robert H Lurie Comprehensive Cancer Center of Northwestern University Ellin Berman MD Memorial Sloan Kettering Cancer Center Ravi Bhatia MD University of Alabama at Birmingham Comprehensive Cancer Center Bhavana Bhatnagar DO The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute Peter Curtin MD UC San Diego Moores Cancer Center Daniel J DeAngelo MD PhD Dana Farber Brigham and Women s Cancer Center Michal G Rose MD Yale Cancer Center Smilow Cancer Hospital Neil P Shah MD PhD UCSF Helen Diller Family Comprehensive Cancer Center B Douglas Smith MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins David S Snyder MD City of Hope Comprehensive Cancer Center Kendra L Sweet MD MS Moffitt Cancer Center Moshe Talpaz MD University of Michigan Rogel Cancer Center James Thompson MD Roswell Park Comprehensive Cancer Center David T Yang MD University of Wisconsin Carbone Cancer Center NCCN Guidelines Index Table of Contents Discussion Version 1 2019 08 01 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Version 1 2019 Chronic Myeloid Leukemia Printed by Maria Chen on 8 1 2018 9 22 15 PM For personal use only Not approved for distribution Copyright 2018 National Comprehensive Cancer Network Inc All Rights Reserved NCCN Chronic Myeloid Leukemia Panel Members Summary of Guidelines Updates Workup CML 1 Chronic Phase CML Primary Treatment CML 2 Early Treatment Response Milestones Clinical Considerations and Second line Treatment CML 3 Advanced Phase CML Primary Treatment CML 4 Treatment Options Based on BCR ABL1 Mutation Profile CML 5 Allogeneic Hematopoietic Cell Transplantation CML 6 Risk Calculation Table CML A Definitions of Accelerated Phase and Blast Phase CML B Monitoring Response to TKI Therapy and Mutational Analysis CML C Criteria for Hematologic Cytogenetic and Molecular Response and Relapse CML D Criteria for Discontinuation of TKI Therapy CML E Management of Toxicities CML F Management of Bosutinib Toxicity CML F 1 of 6 Management of Dasatinib Toxicity CML F 2 of 6 Management of Imatinib Toxicity CML F 3 of 6 Management of Nilotinib Toxicity CML F 4 of 6 Management of Omacetaxine Toxicity CML F 5 of 6 Management of Ponatinib Toxicity CML F 6 of 6 The NCCN Guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient s care or treatment The National Comprehensive Cancer Network NCCN makes no representations or warranties of any kind regarding their content use or application and disclaims any responsibility for their application or use in any way The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network All rights reserved The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN 2018 Clinical Trials NCCN believes that the best management for any patient with cancer is in a clinical trial Participation in clinical trials is especially encouraged To find clinical trials online at NCCN Member Institutions click